The story
On 1 April 2013, Czechia created a legal route for patients to receive cannabis as medicine. Act No. 50/2013 put treatment inside a controlled prescription-and-pharmacy system; it did not authorise patients to grow their own plants.
From proposal to law
A government working group on access to cannabis for treatment and research began work in 2011. Its bill passed the Chamber of Deputies on 7 December 2012 and the Senate on 30 January 2013. President Václav Klaus signed it on 15 February, and it was promulgated as Act No. 50/2013 on 4 March.
Most of the amendments took effect on 1 April. Provisions needed for domestic cultivation, grower selection, processing and transport were delayed until April 2014 while the State Institute for Drug Control, SÚKL, built the system.
Prescription and pharmacy only
The law required a doctor with an eligible specialist qualification. Cannabis would be supplied through pharmacies on an electronic prescription, with indications and maximum quantities controlled through a register. The system was designed to track dispensing and prevent a patient from exceeding the applicable limit.
The government’s summary identified pain, spasms, nausea and vomiting associated with serious illness among the intended therapeutic uses. It listed conditions including chronic neuropathic or cancer pain, HIV/AIDS wasting and polyneuropathy, certain skin diseases and painful glaucoma.
Supply, not personal growing
The first phase could use imported cannabis under Ministry of Health supervision. Licensed domestic cultivation was to follow, but only within the state-controlled programme. The act explicitly did not allow individual growing for medical use.
Implementation took time. The first Czech-grown medical batch reached distribution in 2016, public insurance began covering most of a standard monthly quantity in 2020, and general practitioners gained limited prescribing authority in 2025.
What moved in the index
Medical legalisation raised Czechia’s access score from 0 to 1. Possession, cultivation, enforcement, sharing and consumption did not move: the new route applied only to qualifying patients using prescribed cannabis dispensed through pharmacies, while the ordinary personal-use rules remained unchanged.
That narrow movement captures the reform’s scope: a patient gained a lawful clinical channel, but other adults did not gain a lawful source or a defence for growing cannabis as medicine.[1][2]
Score by segment 0 to 10
- Possession · 25%3 → 3
- Personal cultivation · 25%2 → 2
- Punishment & enforcement · 20%5 → 5
- Sharing & gifting · 10%1 → 1
- Consumption · 10%4 → 4
- Legal access · 10%0 → 1+1
The bar shows the score after the change; the tick marks where it stood before. Czechia's scores have changed again since.
References
Checked. The date and the event were compared with a source that was read. The score before the change is an editorial estimate.